Compare AstraZeneca plc (AZN) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Meta Platforms Inc — how do they compare? AstraZeneca plc trades at $158.28 (market cap $248.14B), while Meta Platforms Inc trades at $580.31 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 6.2× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | META | |
|---|---|---|
Market Cap | $248.14B | $1.53T |
Sector | Health | Media |
52-Week High | $209.48 | $790.00 |
52-Week Low | $147.06 | $525.72 |
Enterprise Value | $275.41B | $1.55T |
Dividend Yield | 2.01% | 0.35% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
META trades at $579.51, down 2.59% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $200.97B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a legal ruling in Massachusetts regarding youth addiction lawsuits.
The outlook remains positive with a consensus price target of $761.95 and 79% buy ratings from analysts, driven by AI innovation and solid fundamentals. Risks include regulatory challenges and high capital expenditures, but earnings beats and institutional buying support long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
